Hodgkin Lymphoma, Lymphoma, Non-hodgkin Lymphoma
Conditions
Keywords
lymphoma, Hodgkin lymphoma, Non-Hodgkin lymphoma, THRLBCL, DLBCL, MZL, CLL/SLL, MCL, WM
Brief summary
The aim of this study is to describe the clinical and genetic characteristics of Chinese lymphoma patients, and to explore the relationship between those characteristics and phatogenesis.
Detailed description
Lymphoma is a highly common malignant tumor in Asia. This study aims to observe and describe the clinical and genetic charateristics of Chinese lymphoma patients, and to explore the relationship between those charateristics and pathogenesis and prognostic factors in the real-world population. This study is a non-interventional real world, observational study and all registered data are collected from real clinical practice cases. The medical data includes patient demographic, tumor characteristics, laboratory examination, history of treatments, adverse reactions, efficacy results and possible prognostic factors.
Interventions
OTHERReal-world regimen
The final personalized management strategy is determined based on current conventional treatment options, physician and patient preferences.The following protocols: chemotherapy, immunochemotherapy,Anti-cd20 monoclonal antibody, BTKi and so on
Sponsors
Shanghai Zhongshan Hospital
Study design
Observational model
COHORT
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Patients with pathological diagnosis of lymphoma (including Hodgkin lymphoma and non-Hodgkin lyphoma, eg. THRLBCL, DLBCL, MZL, CLL/SLL...) from 2007 to 2027. * Patients with complete diagnostic, treatment and follow-up records. * Fully comprehension and signature of the informed consent form (ICF) for participation.
Exclusion criteria
* Those who refuse to use reliable methods of contraception during pregnancy, lactation or age-appropriate period. * Severe mental illness. * Patients deemed unsuitable for inclusion by the investigator.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| OS | Baseline up to data cut-off (Up to approximately 20 years) | Overall survival (OS) refers to the time from receiving the first dose to death from any cause |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| PFS | Baseline up to data cut-off (Up to approximately 20 years) | Progression-free survival (PFS) is defined as the time from the date of first administration to the date of first disease progression or death from any cause, whichever occurs first. |
Countries
China
Contacts
Primary ContactPeng Liu, Ph.D
Outcome results
None listed